CMS Ended Federal Funding for Pediatric Gender Interventions
New policy limits Medicaid and CHIP coverage for sex-rejecting medical procedures for patients under 19.
Updated on Oct. 13, 2026 in Children’s Health
Live Poll
Should federal Medicaid and CHIP funds cover gender-affirming medical treatments for children?
The Centers for Medicare & Medicaid Services has officially prohibited federal funding for gender-affirming medical interventions for minors. This change applies to Medicaid and CHIP beneficiaries, though mental health services remain eligible for federal coverage.
Why it matters
This rule impacts how families access gender-related medical care by removing federal financial participation for specific pediatric interventions. The decision follows a federal determination that current clinical evidence supporting the benefits of these treatments for minors is of very low quality.
The federal rule, which drew approximately 11,000 public comments, ends funding for puberty blockers and surgeries identified as sex-rejecting procedures. It excludes treatments for precocious puberty and disorders of sexual development from this prohibition.
The players
Centers for Medicare & Medicaid Services
The federal agency responsible for administering the Medicaid and CHIP programs and establishing national coverage policies.
The details
The regulation restricts federal financial participation rather than the clinical practice of medicine itself. Providers may continue to bill Medicaid and CHIP for medications and procedures if they are utilized for non-gender-affirming medical purposes. A six-month tapering period has been established for children currently receiving cross-sex hormone therapy, which concludes in April 2027.
Timeline
December 19, 2025: Proposed rule was first published.
October 13, 2026: Rule took effect and federal funding ended.
April 2027: End of the six-month tapering period for hormone therapy.
Health Landscape
The new CMS rule aligns with clinical policy shifts observed in Sweden, Finland, and the United Kingdom regarding pediatric gender interventions. It marks a departure from previous federal funding standards by prioritizing the agency's assessment of treatment evidence quality.
Families affected by this change should consult their healthcare provider to discuss how this policy impacts current treatment plans and coverage. Questions regarding ongoing mental health services or alternative medical necessity billing should be directed to your local Medicaid or CHIP representative.
The takeaway
This policy change specifically targets the use of federal funds for gender-affirming interventions in pediatric populations. Patients and guardians should coordinate with their medical providers to navigate the upcoming transition periods for ongoing treatments.
What happens next
The six-month tapering period for patients currently receiving hormone therapy is scheduled to conclude in April 2027.
Further reading
For more on evolving standards of care, visit Children’s Health.
More information
View the Final federal rule on Medicaid funding via the Federal Register.
Live Poll
Should federal Medicaid and CHIP funds cover gender-affirming medical treatments for children?
